The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)341
JournalCancers
Volume11
Publication statusPublished - 2019

Cite this